Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy

BACKGROUND: Tumor mutation burden (TMB) is a promising biomarker positively associated with the benefit of immunotherapy and that might predict the outcome of chemotherapy. We described the prognostic value of TMB in advanced gastric cancer and explored the underlying mechanism. METHODS: We enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Xiao-Peng, Liu, Ke, Jiao, Xiao-Dong, Qin, Bao-Dong, Li, Bing, He, Xi, Ling, Yan, Wu, Ying, Chen, Shi-Qi, Zang, Yuan-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847361/
https://www.ncbi.nlm.nih.gov/pubmed/36686739
http://dx.doi.org/10.3389/fonc.2022.1007146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847361/
https://www.ncbi.nlm.nih.gov/pubmed/36686739
http://dx.doi.org/10.3389/fonc.2022.1007146

Ejemplares similares